Abstract
Nanoparticle drug delivery has been promoted as an effective mode of delivering antineoplastic therapeutics. However, most nanoparticle designs fail to consider the multifaceted tumor microenvironment (TME) that produce pro-tumoral niches, which are often resistant to chemo- and targeted therapies. In order to target the chemoresistant cancer stem-like cells (CSCs) and their supportive TME, in this chapter we describe a nanoparticle-based targeted co-delivery that addresses the paracrine interactions between CSC and non-cancerous mesenchymal stem cells (MSCs) in the TME. Carcinoma-activated MSCs have been shown to increase the chemoresistance and metastasis of CSC. Yet their contributions to protect the CSC TME have not yet been systematically investigated in the design of nanoparticles for drug delivery. Therefore, we describe the fabrication of degradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles (120–200 nm), generated with an electrospraying process that encapsulates both a conventional chemotherapeutic, paclitaxel, and a targeted tyrosine kinase inhibitor, sunitinib, to limit MSC interactions with CSC. In the 3D hetero-spheroid model that comprises both CSCs and MSCs, the delivery of sunitinib as a free drug disrupted the MSC-protected CSC stemness and migration. Therefore, this chapter describes the co-delivery of paclitaxel and sunitinib via PLGA nanoparticles as a potential targeted therapy strategy for targeting CSCs. Overall, nanoparticles can provide an effective delivery platform for targeting CSCs and their TME together. Forthcoming studies can corroborate similar combined therapies with nanoparticles to improve the killing of CSC and chemoresistant cancer cells, thereby improving treatment efficiency.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ghoneum A, Afify H, Salih Z et al (2018) Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget 9:22832–22849
Al-Alem LF, Pandya UM, Baker AT et al (2019) Ovarian cancer stem cells: what progress have we made? Int J Biochem Cell Biol 107:92–103
Lupia M, Cavallaro U (2017) Ovarian cancer stem cells: still an elusive entity? Mol Cancer 16:64
Stack MS, Nephew KP, Burdette JE, Mitra AK (2018) The tumor microenvironment of high grade serous ovarian cancer. Cancers (Basel) 11:21
Steg AD, Bevis KS, Katre AA et al (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18:869–881
Zhang B, Chen F, Xu Q et al (2018) Revisiting ovarian cancer microenvironment: a friend or a foe? Protein Cell 9:674–692
Silva IA, Bai S, McLean K et al (2011) Aldehyde dehydrogenase in combination with CD133 defines Angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71:3991–4001
Landen CN, Goodman B, Katre AA et al (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9:3186–3199
Zhang J, Guo X, Chang DY et al (2012) CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 25:456
Curley MD, Therrien VA, Cummings CL et al (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27:2875–2883
Sharrow AC, Perkins B, Collector MI et al (2016) Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: towards targeted stem cell therapy. Gynecol Oncol 142:341–348
Kryczek I, Liu S, Roh M et al (2012) Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130:29–39
Coffman LG, Choi Y-J, McLean K et al (2016) Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget 7:6916–6932
Cho JA, Park H, Lim EH et al (2011) Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol Oncol 123:379–386
Karnoub AE, Dash AB, Vo AP et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557–563
Ding D-C, Liu H-W, Chu T-Y (2016) Interleukin-6 from ovarian mesenchymal stem cells promotes proliferation, sphere and Colony formation and tumorigenesis of an ovarian cancer cell line SKOV3. J Cancer 7:1815–1823
McLean K, Gong Y, Choi Y et al (2011) Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 121:3206–3219
Raghavan S, Snyder CS, Wang A et al (2020) Carcinoma-associated mesenchymal stem cells promote chemoresistance in ovarian cancer stem cells via PDGF signaling. Cancers (Basel) 12:2063
Mitchell MJ, Billingsley MM, Haley RM et al (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20:101
Begines B, Ortiz T, Pérez-Aranda M et al (2020) Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials 10:1403
Danhier F, Lecouturier N, Vroman B et al (2009) Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133:11–17
Fonseca C, Simões S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83:273–286
Li M, Czyszczon EA, Reineke JJ (2013) Delineating intracellular pharmacokinetics of paclitaxel delivered by PLGA nanoparticles. Drug Deliv Transl Res 3:551–561
Mu L, Feng SS (2003) A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J Control Release 86:33–48
Alshetaili AS, Anwer MK, Alshahrani SM et al (2018) Characteristics and anticancer properties of Sunitinib malate-loaded poly-lactic-co-glycolic acid nanoparticles against human colon cancer HT-29 cells lines. Trop J Pharm Res 17:1263–1269
Joseph JJ, Sangeetha D, Gomathi T (2016) Sunitinib loaded chitosan nanoparticles formulation and its evaluation. Int J Biol Macromol 82:952–958
Saber MM, Bahrainian S, Dinarvand R, Atyabi F (2017) Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles. Int J Pharm 517:269–278
Dudek AZ, Nguyen S (2008) Safety of nab-paclitaxel plus Sunitinib: analysis of three cases. Anticancer Res 28:3099–3105
Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: an update. Bioeng Transl Med 4:e10143
Zhang L, Huang J, Si T, Xu RX (2012) Coaxial electrospray of microparticles and nanoparticles for biomedical applications. Expert Rev Med Devices 9:595–612
Mehta P, Novak C, Raghavan S et al (2018) Self-renewal and CSCs in vitro enrichment: growth as floating spheres. In: Papaccio G, Desiderio V (eds) Methods in molecular biology: cancer stem cells: methods and protocols, pp 61–75
Bregenzer ME, Davis C, Horst EN et al (2019) Physiologic patient derived 3d spheroids for anti-neoplastic drug screening to target cancer stem cells. J Vis Exp 2019. https://doi.org/10.3791/59696
Bregenzer M, Horst E, Mehta P et al (2022) The role of the tumor microenvironment in CSC enrichment and Chemoresistance: 3D co-culture methods. Methods Mol Biol 2424:217–245
Almería B, Gomez A (2014) Electrospray synthesis of monodisperse polymer particles in a broad (60nm–2μm) diameter range: guiding principles and formulation recipes. J Colloid Interface Sci 417:121–130
Acknowledgements
This work is supported primarily by the American Cancer Society Research Scholar Award RSG-19-003-01-CCE (G.M.), the Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program, under award no. W81XWH-13-1-0134 (G.M.), W81XWH-16-1-0426 (G.M.), DOD Investigator Initiated award W81XWH-18-0346 (G.M.), Michigan Ovarian Cancer Alliance (G.M.), and NSF EFRI DChem (award number 2029139, G.M. A.T.). Research reported in this publication was supported by the National Cancer Institute under award number P30CA046592 and by the National Institutes of Health under grant number UL1TR002240.
Author Contributions
Conceptualization, G.M., A.T.; formal analysis, C.S.S., K.M.B., T.R., G.M., A.T.; writing–original draft preparation, C.S.S., K.M.B., T.R., G.M.; writing–review and editing, C.S.S., K.M.B., T.R., G.M., A.T.; supervision, G.M., A.T.; funding acquisition, G.M., A.T. All authors have read and agreed to this version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Snyder, C.S., Repetto, T., Burkhard, K.M., Tuteja, A., Mehta, G. (2024). Co-Delivery Polymeric Poly(Lactic-Co-Glycolic Acid) (PLGA) Nanoparticles to Target Cancer Stem-Like Cells. In: Papaccio, F., Papaccio, G. (eds) Cancer Stem Cells. Methods in Molecular Biology, vol 2777. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3730-2_14
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3730-2_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3729-6
Online ISBN: 978-1-0716-3730-2
eBook Packages: Springer Protocols